I think the FDA has now given a route-map to approval, and so subsequent entrants will have an easier time of it than MNTA did. The Amphastar disclosures added to my conviction on this.
I just don't find any of the evidence to the contrary pointed to on this board that convincing.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.